Last updated: September 29, 2026
Hydroxyzine is a mature, low-cost generic antihistamine with limited API-level patent protection and modest commercial differentiation. The strongest excipient opportunities are pediatric liquids, taste-masked solid doses, orally disintegrating tablets, preservative systems, and formulations that improve dose flexibility or reduce administration burden. Commercial success depends on manufacturing cost, stability, supply reliability, and channel access rather than exclusivity on hydroxyzine itself.
Hydroxyzine Excipient Strategy, Patent Position, and Commercial Opportunities
What is hydroxyzine and which formulations are commercially relevant?
Hydroxyzine is a first-generation antihistamine marketed primarily as hydroxyzine hydrochloride and hydroxyzine pamoate. The two salts have similar pharmacologic activity but differ in physical properties, dosage-form history, and formulation considerations.
| Attribute |
Hydroxyzine hydrochloride |
Hydroxyzine pamoate |
| Primary product forms |
Tablets, oral solution, injection |
Capsules, oral dosage forms |
| Common strengths |
10 mg, 25 mg, 50 mg tablets; 10 mg/5 mL oral solution |
25 mg, 50 mg, 100 mg capsules |
| Key uses |
Pruritus, anxiety, preoperative or postoperative sedation |
Anxiety, pruritus |
| Formulation profile |
Water-soluble salt; suitable for aqueous liquids |
Less water-soluble salt; commonly used in capsules |
| Main excipient challenges |
Taste, precipitation risk, preservative compatibility, microbial control |
Wetting, dissolution, powder flow, capsule-fill uniformity |
| Regulatory status |
Generic prescription drug |
Generic prescription drug |
Hydroxyzine products are approved for anxiety, pruritus, and sedation-related indications, depending on the salt and dosage form. U.S. reference products include Atarax and Vistaril, although the commercial market is supplied primarily by generic manufacturers.[1–3]
What is the FDA regulatory status of hydroxyzine?
Hydroxyzine is an approved prescription drug marketed through abbreviated new drug applications and legacy new drug applications. Generic products are approved under the FDA’s ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.
Hydroxyzine is not a biologic and has no biosimilar pathway. The relevant competitive products are generic tablets, capsules, oral liquids, and injectable products.
Key FDA regulatory characteristics
| Regulatory issue |
Hydroxyzine position |
| FDA approval pathway |
Legacy NDA and ANDA products |
| Generic competition |
Extensive |
| Biosimilar exposure |
Not applicable |
| Controlled-substance status |
Not a controlled substance |
| Prescription status |
Prescription drug in the United States |
| Pediatric use |
Relevant, particularly for oral liquid development |
| Orange Book role |
Identifies reference-listed drugs and approved generic equivalents |
| Exclusivity opportunity |
No meaningful current new-drug exclusivity for the established molecule |
Hydroxyzine’s age and extensive generic availability reduce the regulatory value of a standard tablet or capsule. A new product generally needs a differentiated delivery system, a new route, a meaningful patient-population benefit, or a commercially useful combination.
What is the Orange Book status of hydroxyzine?
Current Orange Book records identify hydroxyzine hydrochloride and hydroxyzine pamoate reference products and their approved generic equivalents. The established products do not have a commercially significant active Orange Book patent barrier comparable to newer branded drugs.[4]
The practical consequence is that an applicant normally cannot rely on hydroxyzine’s active ingredient for market exclusivity. Any defensible intellectual-property position would more likely relate to:
- A specific excipient system
- A controlled-release profile
- A taste-masking architecture
- An orally disintegrating dosage form
- A novel combination product
- A manufacturing process
- A device or packaging configuration
- A new method of use, if legally and clinically supportable
An excipient combination by itself may be difficult to protect unless it produces a demonstrated technical effect, such as improved stability, dissolution, palatability, dose uniformity, or reduced preservative exposure.
When did hydroxyzine lose core patent exclusivity?
Hydroxyzine’s core composition and conventional dosage-form exclusivity expired decades ago. The current generic market reflects the absence of an effective API-level barrier.
Exact patent histories are difficult to use commercially because the principal hydroxyzine products predate modern Orange Book listing practices and the active commercial landscape is no longer controlled by those historical rights. Current product-level competition is governed by ANDA approval, manufacturing economics, supply capacity, and state and federal purchasing channels.
Exclusivity timeline
| Period |
Commercial position |
| Original launch period |
Branded hydroxyzine products introduced |
| Historical patent term |
Core molecule and conventional products moved beyond patent exclusivity |
| Modern generic period |
Multiple ANDA-approved manufacturers entered |
| Current market |
Mature, multisource generic market with limited product differentiation |
No current 30-month Orange Book patent stay or major Paragraph IV campaign is a central feature of the hydroxyzine market based on public FDA product information.[4]
Which excipient strategy is best for hydroxyzine tablets and capsules?
For conventional tablets and capsules, the highest-value excipient strategy is usually operational rather than patent-driven. The objective is to improve manufacturability, stability, dose uniformity, and patient acceptability at a low bill-of-materials cost.
Hydroxyzine hydrochloride tablets
Hydroxyzine hydrochloride is suitable for immediate-release tablets using standard excipient platforms:
- Microcrystalline cellulose or dibasic calcium phosphate for compactability
- Crospovidone, croscarmellose sodium, or sodium starch glycolate for disintegration
- Magnesium stearate or sodium stearyl fumarate for lubrication
- Colloidal silicon dioxide for flow control
- Film coatings for color, swallowability, and light protection
The main development risks are low-dose content uniformity, tablet friability, over-lubrication, and sensory acceptability. A 10 mg tablet creates more demanding blend-uniformity requirements than a 50 mg tablet because the active represents a smaller fraction of total tablet mass.
Hydroxyzine pamoate capsules
Hydroxyzine pamoate presents a different formulation problem. The pamoate salt has lower water solubility than hydroxyzine hydrochloride, making wetting, dissolution, and particle-size control more important.
Relevant excipient levers include:
- A surfactant or wetting agent to improve powder hydration
- Colloidal silica to improve flow and reduce segregation
- Lactose, mannitol, or microcrystalline cellulose as fillers
- A disintegrant where capsule plug behavior limits dispersion
- Particle-size engineering or micronization of the active ingredient
- Low-moisture processing where water uptake affects stability or flow
A capsule formulation with strong dissolution performance across physiologic pH conditions may offer a practical product advantage, but the benefit must be demonstrated against the reference product through comparative dissolution and bioequivalence studies.
What excipients are most attractive for hydroxyzine oral liquids?
Oral liquid products offer the clearest near-term excipient opportunity because hydroxyzine has pediatric and geriatric use cases, while first-generation antihistamines can have a strong bitter or medicinal taste.
A commercially viable oral liquid requires control of taste, chemical stability, microbial quality, viscosity, and dose measurement.
Core excipient categories
| Function |
Candidate excipient approach |
Commercial purpose |
| Taste masking |
Sweetener, flavor, polymeric coating, ion-pairing, or complexation |
Improves adherence and pediatric acceptance |
| Viscosity |
Glycerin, sorbitol, hydroxyethylcellulose, xanthan gum |
Reduces sedimentation and improves dosing |
| Buffering |
Citrate, phosphate, or other compatible buffer |
Controls pH and stability |
| Preservation |
Sodium benzoate, potassium sorbate, or other validated system |
Controls microbial growth |
| Solubilization |
Cosolvent or surfactant system |
Maintains hydroxyzine in solution |
| Color and appearance |
Approved color system or clear formulation |
Supports product identification |
| Dose measurement |
Oral syringe-compatible viscosity and packaging |
Reduces administration error |
Taste masking should be developed alongside pH and preservative selection. A highly acidic or alkaline formulation may improve chemical stability but can worsen taste, irritate the mouth, or reduce compatibility with packaging components.
A sugar-free and alcohol-free product can target pediatric, diabetic, institutional, and caregiver markets. However, polyol systems may create gastrointestinal tolerability issues, while high-viscosity systems can interfere with oral-syringe dose withdrawal.
What formulation patents could protect a hydroxyzine product?
A new hydroxyzine product would have a stronger patent position if the formulation solves a documented technical problem. The most credible claim areas are:
Taste-masked hydroxyzine
Potential claim elements include:
- Hydroxyzine particles coated with a pH-sensitive polymer
- Ion-exchange resin complexes
- Lipid or polymeric granules
- Multiparticulates incorporated into a liquid or orally disintegrating tablet
- Defined dissolution behavior in simulated saliva and gastric media
Taste-masking claims require careful proof. A formulation that merely contains a sweetener or flavor may have weak patent value. A measurable reduction in bitterness, coupled with stable release and bioequivalence, is more defensible.
Orally disintegrating tablets
An ODT could target patients who have difficulty swallowing conventional tablets. Relevant technical parameters include:
- Disintegration time
- Mechanical strength
- Moisture sensitivity
- Packaging requirements
- Palatability
- Dose loading
Hydroxyzine’s bitter taste makes direct-compression ODT development less attractive unless the active is taste-masked or incorporated into coated particles.
Modified-release products
A sustained-release hydroxyzine product could reduce dosing frequency or smooth sedative effects. The commercial case is uncertain because hydroxyzine is inexpensive and commonly used as needed. Development would require a clear clinical rationale, not only a release-profile difference.
Pediatric liquid systems
A stable, preservative-efficient, taste-masked liquid with a calibrated oral syringe may support a differentiated product. The most defensible IP would likely cover the formulation ranges and the specific stability or sensory performance achieved by the system.
What are the main commercial opportunities for hydroxyzine excipients?
The strongest opportunities are niche products that reduce a practical administration problem.
1. Pediatric-ready oral solution
A sugar-free, alcohol-free, taste-masked liquid could compete in pediatric and caregiver channels. The product should support accurate dosing at low volumes and remain stable after opening under realistic in-use conditions.
2. Hydroxyzine ODT
An ODT could serve patients with dysphagia, anxiety-related difficulty swallowing, or limited access to water. Commercial differentiation depends on acceptable taste and packaging that controls moisture.
3. Unit-dose institutional packaging
Hospitals, long-term-care facilities, correctional systems, and behavioral-health settings may value unit-dose packaging, barcoding, and ready-to-administer formats. Packaging and workflow integration may generate more commercial value than a new excipient alone.
4. High-quality generic supply
For a mature generic, consistent supply can be a meaningful competitive advantage. Formulations that use globally available excipients, avoid complex controlled-temperature handling, and maintain robust process capability can reduce stockout risk.
5. Private-label and contract-manufacturing platforms
Hydroxyzine is suitable for multi-client platforms involving tablets, capsules, and oral liquids. A manufacturer with validated excipient systems can reduce development cost for private-label customers and regional distributors.
Which companies are challenging hydroxyzine patents?
No major active patent-challenge campaign is central to the hydroxyzine market. Competition comes primarily from generic manufacturers that have already entered after expiration of the historical exclusivity period.
The relevant competitive groups include:
- Large generic pharmaceutical companies
- Regional ANDA holders
- Contract manufacturers
- Specialty suppliers of oral liquids
- Private-label distributors
- Institutional-dose packagers
A Paragraph IV strategy has limited economic appeal where the reference product has no commercially meaningful blocking patent. The cost of litigation would be difficult to justify unless a new branded hydroxyzine formulation obtained method-of-use or formulation patents.
What patent litigation and settlement risks affect hydroxyzine?
Conventional hydroxyzine tablets, capsules, and oral solutions have low expected patent-litigation exposure. A new branded formulation would create a different risk profile.
Potential litigation triggers
- Broad formulation claims that overlap with generic products
- Method-of-use claims covering common anxiety or pruritus treatment
- ODT claims that rely on standard disintegrant systems
- Taste-masking claims with narrow but commercially important ranges
- Patent listings that delay ANDA approval
- Trade-secret disputes over manufacturing or sensory-masking processes
Settlement agreements are not a major feature of the established hydroxyzine market. Any future settlement would more likely involve a newly patented delivery system than the hydroxyzine molecule itself.
How strong is the hydroxyzine patent estate?
The core hydroxyzine patent estate is weak from a current commercial-exclusivity perspective. The molecule is old, products are multisource, and conventional dosage forms have generic substitutes.
A new formulation estate could be moderate if it has:
- A clearly defined technical problem.
- Comparative data against existing hydroxyzine products.
- Narrow but commercially meaningful composition claims.
- Manufacturing claims that are difficult to design around.
- A clinically relevant benefit, such as improved adherence or reduced dosing frequency.
Patent strength would be low for claims based only on routine excipient substitution, standard sweeteners, ordinary tablet disintegrants, or conventional capsule fillers.
How does hydroxyzine compare with competing antihistamines?
Hydroxyzine competes with cetirizine, levocetirizine, diphenhydramine, and other antihistamines. It also competes with non-antihistamine agents in anxiety and pruritus treatment.
| Product |
Generic maturity |
Sedation profile |
Excipient opportunity |
Commercial differentiation |
| Hydroxyzine |
Very high |
Higher |
Taste masking, pediatric liquid, ODT |
Administration and supply |
| Diphenhydramine |
Very high |
Higher |
Liquids, chewables, unit dose |
Retail availability |
| Cetirizine |
High |
Lower |
Liquids, chewables, ODT |
Lower sedation positioning |
| Levocetirizine |
High |
Lower to moderate |
Liquids and pediatric formats |
Brand and formulation positioning |
Hydroxyzine’s sedating properties limit direct substitution with newer, less-sedating antihistamines in some allergy markets. They also create a potential formulation opportunity for controlled dosing and improved caregiver administration, although any product positioning must remain consistent with the approved label.
What generic launch scenarios exist for a new hydroxyzine product?
Low-investment scenario
A conventional tablet or capsule with standard excipients can enter a mature market quickly but will face price competition and limited differentiation.
Moderate-investment scenario
A sugar-free, taste-masked oral liquid can target pediatric and institutional customers. The main risks are stability, preservative validation, and price pressure from existing liquids.
Higher-investment scenario
An ODT, modified-release product, or novel multiparticulate formulation could support branded positioning and formulation patents. The development burden is higher, and clinical or bioequivalence advantages must justify the cost.
Premium specialty scenario
A product combining hydroxyzine with a proprietary delivery device, unit-dose packaging, or a clinically differentiated dosing regimen could support licensing or specialty distribution. The addressable market would be narrower but less exposed to commodity pricing.
What licensing opportunities exist for hydroxyzine formulations?
Licensing interest is most plausible for technologies that can be applied across multiple mature drugs. A hydroxyzine product could serve as a demonstration product for:
- Taste-masking platforms
- Pediatric liquid systems
- ODT technology
- Multiparticulate coating
- Low-dose blend-uniformity processes
- Unit-dose packaging
- Stability-enhancing excipient systems
A platform license is more attractive than a hydroxyzine-only license when the underlying technology can be extended to diphenhydramine, cetirizine, promethazine, or other difficult-to-taste oral drugs.
What geographic markets offer the best opportunity?
The United States has high generic competition and limited API-level exclusivity. The most attractive opportunities are differentiated formats and reliable supply rather than basic tablets.
Potential regional priorities include:
- United States: specialty liquids, ODTs, institutional packaging
- European Union: pediatric and patient-friendly dosage forms, subject to national reimbursement
- Emerging markets: stable oral liquids, affordable tablets, local manufacturing
- Long-term-care markets: unit-dose packaging and medication-administration compatibility
Geographic expansion requires country-specific review of approved strengths, excipient permissions, flavor requirements, labeling, and reference-product standards. A formulation approved in the United States may require separate stability and packaging support in other jurisdictions.
What manufacturing and IP barriers matter most?
The main manufacturing barriers are not chemical synthesis. They are:
- Uniform low-dose blending
- Control of hydroxyzine pamoate dissolution
- Taste-masking reproducibility
- Oral-liquid microbial control
- Preservative compatibility
- Moisture protection for ODTs
- Capsule-fill consistency
- Global excipient supply
- Packaging performance after opening
The most valuable manufacturing know-how may remain a trade secret rather than a patent. This is particularly true for flavor systems, coating parameters, granulation endpoints, and process controls that are difficult to infer from the finished product.
Key Takeaways
- Hydroxyzine is a mature generic with no meaningful current API-level exclusivity.
- Hydroxyzine hydrochloride is mainly suited to conventional tablets, oral liquids, and injectable products; hydroxyzine pamoate is commonly used in capsules.
- The best excipient opportunities are taste masking, pediatric liquids, ODTs, unit-dose formats, and stability-focused systems.
- Standard excipient substitution is unlikely to create strong patent protection.
- A defensible formulation patent should link a defined composition to measurable stability, dissolution, palatability, or dosing performance.
- Paragraph IV litigation and settlement activity are not central to the established hydroxyzine market.
- Commercial value is more likely to come from patient administration, supply reliability, and institutional workflow than from molecule-level exclusivity.
- Hydroxyzine is not subject to biosimilar competition.
- A platform license covering taste masking or pediatric delivery may be more valuable than a hydroxyzine-only license.
- The strongest launch candidates are differentiated oral liquids, ODTs, and institutional unit-dose products.
FAQs
Can hydroxyzine be formulated as a sugar-free oral liquid?
Yes. A sugar-free liquid can use polyols, compatible sweeteners, buffering agents, viscosity modifiers, and a validated preservative system. The formulation must demonstrate chemical stability, microbial control, acceptable taste, and accurate dosing.
Does hydroxyzine pamoate require a different excipient strategy from hydroxyzine hydrochloride?
Yes. Hydroxyzine pamoate has lower water solubility and places greater emphasis on wetting, particle size, dissolution, powder flow, and capsule-fill uniformity. Hydroxyzine hydrochloride is more readily adapted to aqueous liquid systems.
Is a hydroxyzine orally disintegrating tablet commercially viable?
It can be viable as a differentiated product for patients with swallowing difficulty, but commercial success depends on taste masking, moisture protection, rapid disintegration, and a price premium over standard generic tablets.
Are new hydroxyzine excipients eligible for patent protection?
Excipients themselves are usually not enough. Protection is more credible when a defined excipient combination produces an unexpected technical result, such as improved palatability, stability, dissolution, or dose uniformity.
Is hydroxyzine suitable for a 505(b)(2) development program?
A 505(b)(2) strategy may be relevant for a genuinely differentiated dosage form, delivery route, or dosing profile that relies partly on existing hydroxyzine data. The commercial case must justify development costs in a heavily genericized market.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Vistaril (hydroxyzine pamoate) prescribing information. https://www.accessdata.fda.gov/
-
DailyMed. (n.d.). Hydroxyzine hydrochloride and hydroxyzine pamoate product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
-
United States Pharmacopeia. (2024). Hydroxyzine hydrochloride and hydroxyzine pamoate monographs. United States Pharmacopeial Convention. https://www.usp.org/for-users-of-the-usp-nf/usp-nf-online
